NEULANDLAB

Neuland Laboratories Share Price

₹15,040.20 +151.15 (1.02%)

21 Nov, 2024 14:08

SIP TrendupStart SIP in NEULANDLAB

Start SIP

Performance

  • Low
  • ₹14,713
  • High
  • ₹15,480
  • 52 Week Low
  • ₹4,926
  • 52 Week High
  • ₹16,561
  • Open Price₹14,880
  • Previous Close₹14,889
  • Volume26,459

Investment Returns

  • Over 1 Month + 6.78%
  • Over 3 Month + 31.05%
  • Over 6 Month + 141.6%
  • Over 1 Year + 178.71%
SIP Lightning

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 69
  • PEG Ratio
  • 13.7
  • Market Cap Cr
  • 19,296
  • P/B Ratio
  • 15.1
  • Average True Range
  • 1060.65
  • EPS
  • 205.86
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 395.5
  • RSI
  • 54.77
  • MFI
  • 49.26

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹15,040.20
+ 151.15 (1.02%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹14,434.90
  • 50 Day
  • ₹13,518.35
  • 100 Day
  • ₹12,024.28
  • 200 Day
  • ₹9,917.18

Resistance and Support

15009.17 Pivot Speed
  • R3 15,756.78
  • R2 15,547.62
  • R1 15,218.33
  • S1 14,679.88
  • S2 14,470.72
  • S3 14,141.43

What's your outlook on Neuland Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system.

Neuland Laboratories has an operating revenue of Rs. 1,528.28 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 61% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-08-01 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.64%
4.04%
0.4%
26.46%
26.5%
9.96%

About Neuland Laboratories

  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹15,040 As on 21 November, 2024 | 13:54

The Market Cap of Neuland Laboratories is ₹19296.4 Cr As on 21 November, 2024 | 13:54

The P/E ratio of Neuland Laboratories is 69 As on 21 November, 2024 | 13:54

The PB ratio of Neuland Laboratories is 15.1 As on 21 November, 2024 | 13:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23